New drug hope for lung damage after transplant
NCT ID NCT03805477
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called nintedanib in 20 people who developed a lung condition called bronchiolitis obliterans syndrome after a stem cell transplant. Participants take the drug daily for 12 months alongside their usual medications. The main goal is to see if the drug is safe and tolerable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS (BO) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinic of Hematology, University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clinic of Respiratory Medicine, University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
King Faisal Specialist Hospital & Research Centre
RECRUITINGRiyadh, 11471, Saudi Arabia
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.